JP2023535724A5 - - Google Patents
Info
- Publication number
- JP2023535724A5 JP2023535724A5 JP2023504527A JP2023504527A JP2023535724A5 JP 2023535724 A5 JP2023535724 A5 JP 2023535724A5 JP 2023504527 A JP2023504527 A JP 2023504527A JP 2023504527 A JP2023504527 A JP 2023504527A JP 2023535724 A5 JP2023535724 A5 JP 2023535724A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline polymorph
- cancer
- approximately
- pharmaceutical composition
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055754P | 2020-07-23 | 2020-07-23 | |
| US63/055,754 | 2020-07-23 | ||
| PCT/US2021/043021 WO2022020747A1 (en) | 2020-07-23 | 2021-07-23 | Polymorophs of 5-aza-4'-thio-2-deoxycytidine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535724A JP2023535724A (ja) | 2023-08-21 |
| JP2023535724A5 true JP2023535724A5 (enExample) | 2024-07-31 |
| JP7679452B2 JP7679452B2 (ja) | 2025-05-19 |
Family
ID=79687860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504527A Active JP7679452B2 (ja) | 2020-07-23 | 2021-07-23 | ５－アザ－４’－チオ－２’－デオキシシチジンの多形 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11447472B2 (enExample) |
| EP (1) | EP4185583A4 (enExample) |
| JP (1) | JP7679452B2 (enExample) |
| KR (1) | KR102866823B1 (enExample) |
| CN (1) | CN115989229A (enExample) |
| AU (1) | AU2021314329A1 (enExample) |
| BR (1) | BR112023001236A2 (enExample) |
| CA (1) | CA3186696A1 (enExample) |
| MX (1) | MX2023000979A (enExample) |
| WO (1) | WO2022020747A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230123277A1 (en) * | 2021-10-15 | 2023-04-20 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease and thalassemia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020322A (en) | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| US20060014949A1 (en) * | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
| CN103951583B (zh) * | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| PL3692983T3 (pl) | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
| WO2011109012A1 (en) | 2010-03-02 | 2011-09-09 | Southern Research Institute | Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents |
| US20110218170A1 (en) | 2010-03-02 | 2011-09-08 | Southern Research Institute | Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents |
| SG11201610551TA (en) | 2014-07-14 | 2017-01-27 | Gilead Sciences Inc | Combinations for treating cancers |
| US20160312261A1 (en) | 2015-04-24 | 2016-10-27 | Plasmia Biotech, S.L. | Enzymatic production of cytosinic nucleoside analogues |
| EP3527226A4 (en) | 2016-10-17 | 2020-06-17 | Daiichi Sankyo Company, Limited | COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR |
| EP3746452B1 (en) * | 2018-02-01 | 2023-09-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides |
| WO2019204637A1 (en) * | 2018-04-19 | 2019-10-24 | Southern Research Institute | 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer |
-
2021
- 2021-07-23 CA CA3186696A patent/CA3186696A1/en active Pending
- 2021-07-23 BR BR112023001236A patent/BR112023001236A2/pt unknown
- 2021-07-23 JP JP2023504527A patent/JP7679452B2/ja active Active
- 2021-07-23 KR KR1020237006092A patent/KR102866823B1/ko active Active
- 2021-07-23 MX MX2023000979A patent/MX2023000979A/es unknown
- 2021-07-23 CN CN202180052138.4A patent/CN115989229A/zh active Pending
- 2021-07-23 WO PCT/US2021/043021 patent/WO2022020747A1/en not_active Ceased
- 2021-07-23 AU AU2021314329A patent/AU2021314329A1/en active Pending
- 2021-07-23 EP EP21845710.9A patent/EP4185583A4/en active Pending
- 2021-07-23 US US17/384,345 patent/US11447472B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524912A5 (enExample) | ||
| US8927530B2 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| JP2021522197A5 (enExample) | ||
| EP3368541A1 (en) | Compositions and methods for inhibiting arginase activity | |
| HRP20100563T1 (hr) | Derivati dihidropirazolopirimidinona | |
| JP2011505386A5 (enExample) | ||
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2010533206A5 (enExample) | ||
| JP2023535724A5 (enExample) | ||
| US20100009906A1 (en) | Anticancer Treatments | |
| JP2020514344A5 (enExample) | ||
| KR20210092204A (ko) | 비산트렌 제형의 제조 및 전달을 위한 방법 | |
| CN114469949A (zh) | 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物 | |
| US20040006023A1 (en) | Antitumor theraphy comprising distamycin derivatives | |
| AU2002221622A1 (en) | Antitumor therapy comprising distamycin derivatives | |
| EA016873B1 (ru) | Применение для лечения лейкемии | |
| JP2024506847A5 (enExample) | ||
| CN111989092A (zh) | Bet抑制剂和蛋白酶体抑制剂的联合治疗 | |
| KR102501514B1 (ko) | 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물 | |
| US12297175B2 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor | |
| US20230099876A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
| US20230074698A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor | |
| CN102448454B (zh) | 包含plk1抑制剂和抗肿瘤剂的治疗性组合 | |
| US20230098888A1 (en) | Drg-mdm2-6 for use as a novel mouse double minute 2 (mdm2) inhibitor | |
| CA3217787A1 (en) | Method for treating blood cancers |